Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma.

International immunopharmacology - 1 Nov 2023

Mo Zeming, Liu Jie, Zhang Jinyan, Deng Yaotiao, Xu Miao, Jiang Yu

Abstract excerpt

OBJECTIVES: This study evaluates the efficacy of programmed death-1 (PD-1) inhibitors as adjuvant therapy for acral melanoma (AM) and the predictive value of genetic mutations and tertiary lymphoid structures (TLSs). METHODS AND RESULTS: A single-center retrospective longitudinal cohort study was conducted between October 1, 2018, and September 31, 2022. Patients with stages II-III completely resected AM were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Longitudinal Studies

Share to Melanoma

Share to Melanoma, Cutaneous Malignant

Share to Recurrence

Share to Skin Neoplasms

Source

Identifiers

PMID: 37769536
DOI: 10.1016/j.intimp.2023.110973

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma.PMID 37769536Read ↗

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.Semantic proximity Read ↗

Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation.Semantic proximity Read ↗

A retrospective study of anti-PD-1 combined with temozolomide adjuvant therapy for stage III resected acral melanomaSemantic proximity Read ↗

A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.Semantic proximity Read ↗

Tertiary lymphoid structures improve immunotherapy and survival in melanoma.Semantic proximity Read ↗

LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 TrialsSemantic proximity Read ↗

Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trialSemantic proximity Read ↗

Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis.Semantic proximity Read ↗

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.Semantic proximity Read ↗

Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.Semantic proximity Read ↗

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.Semantic proximity Read ↗

Pembrolizumab in advanced acral lentiginous melanoma: final results of a single-centre, open-label, phase II trial in an East Asian populationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.